Cervical cancer
MONDO:0002974A primary or metastatic malignant neoplasm involving the cervix.
Also known as: cervical neoplasm, tumor of the cervix uteri, tumour of the cervix uteri, uterine cervical neoplasm, cancer of uterine cervix, cervical cancer, somatic, malignant cervical neoplasm, malignant cervical tumor
3477 clinical trials for this condition and its sub-types, 576 tagged with Cervical cancer itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Cervical cancer
-
Cervical carcinoma 257 trials · 317 incl. sub-types
9 sub-types
- Cervical squamous cell carcinoma 36 trials · 40 incl. sub-types Sub-types →
- Cervical adenocarcinoma 27 trials · 34 incl. sub-types Sub-types →
- Uterine cervix carcinoma in situ 15 trials
- Cervical large cell neuroendocrine carcinoma 4 trials
- Cervical small cell carcinoma 4 trials
- Endocervical carcinoma 1 trial · 4 incl. sub-types Sub-types →
- Cervical adenoid basal carcinoma 0 trials
- Exocervical carcinoma 0 trials
- Papillary carcinoma of the cervix uteri 0 trials Sub-types →
-
Malignant neoplasm of endocervix 0 trials · 4 incl. sub-types
1 sub-type
- Endocervical carcinoma 1 trial · 4 incl. sub-types Sub-types →
-
Cervix melanoma 1 trial
-
Malignant mixed epithelial and mesenchymal tumor of cervix uteri 0 trials · 1 incl. sub-types
2 sub-types
- Cervical adenosarcoma 1 trial Sub-types →
- Cervical carcinosarcoma 0 trials
-
Cervical Wilms tumor 0 trials
-
Sarcoma of cervix uteri 0 trials
5 sub-types
-
Uterine ligament cancer 0 trials
2 sub-types
- Uterine ligament adenocarcinoma 0 trials Sub-types →
- Uterine ligament adenosarcoma 0 trials
Most studied deeper sub-types
-
Promising combo for cervical cancer hits roadblock: trial ends early
Disease control Stopped earlyThis phase 2 trial tested a new treatment sequence for stage IB2 to IVA cervical cancer. Patients received a combination of gemcitabine and cisplatin chemotherapy along with radiation, followed by more gemcitabine. The goal was to see if this approach could improve progression-fr…
Phase 2 • Sponsor: Centre Oscar Lambret • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
MRI-Guided radiation: a sharper aim for HPV cancers?
Disease control Stopped earlyThis early-phase trial tests whether using MRI scans to guide the placement of internal radiation (brachytherapy) can improve treatment for women with advanced cervical or vaginal cancers linked to HPV. The study involves 26 participants and compares MRI-guided placement to stand…
Phase 1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New antibody combo shows promise in early cancer trial
Disease control Stopped earlyThis trial tests a new antibody called acasunlimab, alone or with other cancer drugs, in people with advanced solid tumors that have not responded to standard treatments. The study has two parts: first to find safe doses, then to see how well those doses work. About 429 participa…
Phase 1/2 • Sponsor: Genmab • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
Engineered immune cells take aim at Hard-to-Treat cervical cancer
Disease control Stopped earlyThis trial investigates whether specially engineered immune cells (CAR-T cells) can safely treat advanced or recurrent cervical cancer. The cells are designed to recognize and attack cancer cells that carry certain markers like GD2 or Mesothelin. The study involves 20 adults with…
Phase 1/2 • Sponsor: Shenzhen Geno-Immune Medical Institute • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC
-
Engineered immune cells take on Hard-to-Treat cervical cancer
Disease control Stopped earlyThis study tests a new treatment for people with advanced or recurrent cervical cancer linked to high-risk HPV. The treatment uses specially engineered immune cells (CC-EIEs) designed to target and attack the cancer. Participants receive several infusions of these cells, and rese…
Phase 1/2 • Sponsor: Shenzhen Geno-Immune Medical Institute • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC
-
Can a new drug combo revive Immunotherapy's power against resistant tumors?
Disease control Stopped earlyThis trial is testing whether an experimental drug called NC410, when combined with the immunotherapy drug pembrolizumab, can safely and effectively treat people with advanced solid tumors that have not responded to standard immunotherapy or that are unlikely to respond. The stud…
Phase 1/2 • Sponsor: NextCure, Inc. • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Can an immunotherapy-angiogenesis combo outshine standard chemo for advanced cervical cancer?
Disease control Stopped earlyThis phase 2 trial compares a new combination of camrelizumab (an immunotherapy) plus apatinib (a targeted therapy) against the standard chemotherapy plus bevacizumab as a first treatment for women with stage IVB, recurrent, or persistent cervical cancer. The study aims to see if…
Phase 2 • Sponsor: Sun Yat-Sen University Cancer Center • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
Can a Two-Pronged attack shrink Hard-to-Treat cancers?
Disease control Stopped earlyThis trial tests whether an experimental drug called XNW5004, which blocks a protein that helps cancer grow, can boost the effects of the immunotherapy pembrolizumab (Keytruda) in people with advanced solid tumors that have stopped responding to standard treatments. The study inc…
Phase 1/2 • Sponsor: Evopoint Biosciences Inc. • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
New hope for advanced cervical cancer: targeted drug combo shows promise
Disease control Stopped earlyThis trial tested a drug called tisotumab vedotin, alone or with other medicines, in people with cervical cancer that had come back or spread. The study included 214 participants and aimed to find the best dose and see if the tumors shrank. The trial was stopped early, but the re…
Phase 1/2 • Sponsor: Seagen, a wholly owned subsidiary of Pfizer • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
Immune booster added to standard cervical cancer treatment shows promise in early trial
Disease control Stopped earlyThis study tested adding the immune-boosting drug pembrolizumab to standard chemoradiation for people with advanced cervical cancer. The goal was to see if the combination is safe and to find the best dose. Only one person was enrolled before the study was stopped early, so resul…
Phase 1 • Sponsor: Royal Marsden NHS Foundation Trust • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
Experimental TIL therapy for advanced gynecological tumors shows early promise but study halted
Disease control Stopped earlyThis early study tested a new treatment called GT201 for people with advanced gynecological tumors, like advanced cervical cancer. The treatment uses a patient's own immune cells (tumor-infiltrating lymphocytes) to fight the cancer. The study was terminated early after enrolling …
Sponsor: Grit Biotechnology • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
Experimental cancer combo shows early promise but study halted
Disease control Stopped earlyThis early-phase trial tested a new drug called nanrilkefusp alfa, which helps activate immune cells, both alone and combined with the immunotherapy pembrolizumab. It included 115 people with various advanced solid tumors that had stopped responding to standard treatments. The st…
Phase 1 • Sponsor: SOTIO Biotech AG • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
Immunotherapy combo shows promise for advanced cervical cancer
Disease control Stopped earlyThis phase 2 trial tested two immunotherapy drugs, AGEN2034 and AGEN1884, in 211 women with recurrent cervical cancer that had progressed after chemotherapy. One group received AGEN2034 alone, the other received both drugs. The goal was to see if the tumors shrank. The study was …
Phase 2 • Sponsor: Agenus Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
New chemo combo after radiation shows promise for advanced cervical cancer
Disease control Stopped earlyThis study looked at whether adding a specific chemotherapy combination (carboplatin and paclitaxel) after standard chemoradiation could help people with advanced cervical cancer that has spread to lymph nodes near the kidneys. The trial planned to enroll 21 participants but was …
Phase 2 • Sponsor: Centre Oscar Lambret • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
New drug combo for cervical cancer shows early promise, but trial halted
Disease control Stopped earlyThis early-phase trial tested a combination of two drugs—toripalimab (an immunotherapy) and chidamide (a targeted therapy)—in women with advanced cervical cancer that had spread or returned. Only 5 participants were enrolled before the study was terminated. The goal was to see if…
Phase 1/2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New cancer drug tested in people with advanced tumors
Disease control Stopped earlyThis early study tested a new drug called PHN-010 in 26 people with advanced cancers like lung, colon, and ovarian cancer. The drug is designed to deliver a powerful treatment directly to cancer cells. The main goals were to check safety and find the right dose, but the study was…
Phase 1 • Sponsor: Pheon Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New cancer drug OC-001 tested in advanced tumors – trial ends early
Disease control Stopped earlyThis early-phase trial tested an experimental drug called OC-001, given alone or with the immunotherapy avelumab, in 73 people with various advanced or metastatic cancers (like lung, breast, and bladder cancer). The main goals were to check safety and how the drug moves through t…
Phase 1/2 • Sponsor: Ocellaris Pharma, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
Radioactive 'Smart Bomb' for tumours tested in early trial
Disease control Stopped earlyThis early-phase trial tested a radioactive drug designed to seek out and destroy cancer cells in people with advanced solid tumours that had stopped responding to other treatments. The drug targets a protein called IGF-1R found on many cancer cells. The study aimed to find a saf…
Phase 1 • Sponsor: Fusion Pharmaceuticals Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
Experimental cancer drug trial ends early
Disease control Stopped earlyThis early-stage study tested an experimental drug called INCB099318 in people with advanced solid tumors that had stopped responding to standard treatments. The main goal was to check the drug's safety and how the body processes it. The study was terminated early, so results are…
Phase 1 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
Cancer drug study halted early: what we know
Disease control Stopped earlyThis study tested a new drug called LB101 in 25 adults with advanced solid tumors that had stopped responding to standard treatments. The goal was to check safety and see if the drug shrank tumors. The study was terminated early, so results are limited.
Phase 1/2 • Sponsor: Centessa Pharmaceuticals (UK) Limited • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
Gentler cervical screening tool tested, but study cut short
Symptom relief Stopped earlyThis study compared two devices used to collect tissue from the cervix during screening for cervical cancer: the standard Kevorkian curette and a softer cytobrush. The goal was to see if the cytobrush causes less pain while still getting enough cells for diagnosis. Only 3 women w…
Sponsor: University Hospital, Lille • Aim: Symptom relief
Last updated Jun 27, 2026 08:06 UTC
-
Helping with food and housing may boost cancer screening Follow-Up
Knowledge-focused Stopped earlyThis study looked at whether providing support for unmet basic needs—like food, housing, or transportation—helps low-income women attend their colposcopy appointment after an abnormal cervical cancer screening. The trial planned to enroll 72 participants but was stopped early wit…
Sponsor: Washington University School of Medicine • Aim: Knowledge-focused
Last updated Sep 02, 2026 00:00 UTC
-
Could a genetic marker guide future cancer therapies in taiwan?
Knowledge-focused Stopped earlyThis study is measuring how often a specific genetic marker (HLA-A*02:01) and a cancer-related protein (NY-ESO-1) appear in Taiwanese patients with solid tumors like head and neck, liver, lung, breast, and esophageal cancers. By understanding these frequencies, researchers hope t…
Sponsor: PharmaEssentia • Aim: Knowledge-focused
Last updated Jul 24, 2026 00:00 UTC
-
Simple 5-Minute exam may spot hidden pelvic damage after cancer radiation
Knowledge-focused Stopped earlyThis study aimed to find a better way to detect pelvic floor problems caused by radiation treatment for gynecologic cancer. Researchers tested a 5-minute single-digit pelvic exam on 22 patients undergoing chemoradiotherapy for cervical cancer. The goal was to see if this exam cou…
Sponsor: Washington University School of Medicine • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:54 UTC
-
Blood test could spot cervical cancer spread early
Knowledge-focused Stopped earlyThis study looked at whether tumor DNA floating in the blood of cervical cancer patients can help detect early spread of the disease. Researchers took blood samples from 26 patients before, during, and after treatment. The goal was to see if this DNA test could find minimal metas…
Sponsor: Institut Curie • Aim: Knowledge-focused
Last updated Jun 26, 2026 14:53 UTC